预防ERCP后胰腺炎预防措施的使用模式:一项全国性调查研究
该研究通过27题电子问卷向美国胃肠内镜学会会员发放,调查319名ERCP操作者预防ERCP后胰腺炎(PEP)措施的使用模式。结果显示54%在高风险ERCP中频繁使用预防性胰管支架(PPS),89%频繁使用吲哚美辛;不放置PPS者中80%以使用吲哚美辛为主要原因。作者认为吲哚美辛似乎比PPS使用更频繁,可能正在取代PPS成为首选的PEP预防方法。
要点
- 54%的受访者在高风险ERCP中频繁使用预防性胰管支架(PPS)。
- 89%的受访者频繁使用吲哚美辛预防PEP;不放置PPS者中80%因使用吲哚美辛。
- 年ERCP量更高、在教学医院执业、常做胰腺ERCP者更常使用PPS。
核心结论
- 年ERCP量更高、在教学医院执业且定期行胰腺ERCP的医师更可能使用PPS。
- 治疗性ERCP fellowship培训及近期进入执业也与PPS使用相关。
- 吲哚美辛的使用似乎比PPS更频繁,作者认为吲哚美辛正在取代PPS成为首选的PEP预防方法。
研究设计与样本
- 通过基于云端的Qualtrics程序发放27题电子问卷。
- 向美国胃肠内镜学会会员名录中执业于美国的操作者发送邮件邀请,纳入有活跃ERCP执业者自愿完成调查。
- 分析时对数据进行去标识化处理,调查对象共319名受访者。
主要发现
- 受访者中46%报告接受过治疗性内镜 fellowship 培训,37%在教学项目中执业。
- 47%报告年ERCP量超过100例;多数受访者(61%)报告胰腺ERCP占其操作量≤5%。
- 多数受访者使用预防性胰管支架(PPS),54%报告在高风险ERCP中频繁使用。
- PPS最常见指征为插管困难、辅助胆管通路及多次胰管注射。
- 不放置PPS的医师中,使用吲哚美辛是最常见原因(80%)。
关键数值与推荐
- 频繁使用PPS的相关变量:ERCP fellowship培训(P ≤ .001)、在教学项目执业(P ≤ .001)、执业年限<10年(P = .005)、更高操作量(P ≤ .001)、更高胰腺病例比例(P ≤ .001)。
- 多数受访者报告频繁使用吲哚美辛(89%)。
- 不放置PPS的医师中,使用吲哚美辛为最常见原因(80%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Post-ERCP pancreatitis (PEP) is the most frequent adverse event of ERCP. Various prophylactic measures are endorsed by the American Society for Gastrointestinal Endoscopy and the European Society of Gastrointestinal Endoscopy to both lower the incidence of PEP and to decrease its severity. The extent to which these interventions are practiced throughout the United States is unclear. The aim of this study was to describe the utilization pattern of various PEP measures and determine factors that affect utilization of these measures. METHODS: A 27-question electronic survey was distributed using a cloud-based program (Qualtrics). The questions assessed ERCP training, practice setting, experience, practice patterns, and perceptions for PEP prophylaxis interventions. Endoscopists with practices based in the United States listed in the American Society for Gastrointestinal Endoscopy member directory received a survey invitation via e-mail. The invitation outlined the study and contained a link with instructions to complete the voluntary survey if they had an active ERCP practice. Data were de-identified for the purposes of analysis. RESULTS: Of survey respondents (N = 319), 46% reported therapeutic endoscopy fellowship training and 37% practiced in teaching programs. Annualized ERCP volume of >100 cases per year were reported by 47%, with pancreatic ERCP comprising ≤5% of procedure volume reported by the majority of respondents (61%). The majority of respondents used prophylactic pancreatic stent (PPS), and 54% reported frequent use during high-risk ERCP. The most common indications for PPS were difficult cannulation, to assist biliary access, and multiple pancreatic duct injections. Most respondents reported frequent use of indomethacin (89%). Of physicians who did not use PPS, use of indomethacin was the most common reason (80%). Variables associated with frequent use of PPS were ERCP fellowship training (P ≤ .001), practice at a teaching program (P ≤ .001), <10 years in practice (P = .005), higher procedure volume (P ≤ .001), and higher proportion of pancreatic cases (P ≤ .001). CONCLUSIONS: Physicians with higher annual ERCP volume, who teach at hospital-based ERCP practices, and who regularly perform pancreatic ERCP are more likely to use PPS. Therapeutic ERCP fellowship training and recent entry into practice were also associated with PPS utilization. Indomethacin use seems to be more frequent than PPS. Our findings suggest that indomethacin is supplanting PPS as the preferred method of PEP prophylaxis.
引用
- Ashat M, Kandula S, Cote GA, et al. Utilization pattern of prophylactic measures for prevention of post-ERCP pancreatitis: a National Survey Study. Gastrointest Endosc. 2023. PMID: 36738796. doi:10.1016/j.gie.2023.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。